Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

2020/02/04 by Rod S. Taylor, Rebecca J. Taylor, Susan Bayliss +18 · 32 citations
Medicine · #Liver Disease Diagnosis and Treatment #Liver Disease and Transplantation #Hepatitis C virus research

paper · pdf · doi:10.1053/j.gastro.2020.01.043

Citations

• Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study

Cited by

• At the Crossroads of Health and Disease: Consequences of Fat in the Liver
• ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature
• Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery
• Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
• P5CS-coupled proline metabolism manipulates metabolic dysfunction-associated steatotic liver disease
• Acceptability of an integrated care program to identify patients at risk of advanced chronic liver disease in Australian primary care settings
• NAFLD and cardiovascular diseases: a clinical review. [europepmc]
• Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. [europepmc]
• Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. [europepmc]
• Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. [europepmc]
• Diabetic fibrosis. [europepmc]
• FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. [europepmc]
• Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. [europepmc]
• The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. [europepmc]
• NASH limits anti-tumour surveillance in immunotherapy-treated HCC. [europepmc]
• Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. [europepmc]
• Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. [europepmc]
• Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. [europepmc]
• KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. [europepmc]
• Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. [europepmc]
• Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. [europepmc]
• Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. [europepmc]
• Hepatic stellate cells in physiology and pathology. [europepmc]
• Noninvasive proteomic biomarkers for alcohol-related liver disease. [europepmc]
• Current therapies and new developments in NASH. [europepmc]
• GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. [europepmc]
• AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. [europepmc]
• Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. [europepmc]
• Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. [europepmc]
• Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. [europepmc]
• EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [europepmc]